Article Text

other Versions

PDF
Extended report
Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naïve patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study
  1. Jacqueline Detert1,
  2. Hans Bastian1,
  3. Joachim Listing2,
  4. Anja Weiß2,
  5. Siegfried Wassenberg3,
  6. Anke Liebhaber4,
  7. Karin Rockwitz5,
  8. Rieke Alten6,
  9. Klaus Krüger7,
  10. Rolf Rau8,
  11. Christina Simon1,
  12. Eva Gremmelsbacher1,
  13. Tanja Braun1,
  14. Bettina Marsmann1,
  15. Vera Höhne-Zimmer1,
  16. Karl Egerer1,9,
  17. Frank Buttgereit1,
  18. Gerd-R Burmester1
  1. 1Department of Rheumatology and Clinical Immunology, Charité–Universitätsmedizin Berlin, Berlin, Germany
  2. 2German Rheumatism Research Center (DRFZ), Berlin, Germany
  3. 3Department of Rheumatology Clinic, Evangelisches Fachkrankenhaus, Ratingen, Germany
  4. 4Rheumatology practice, Halle, Germany
  5. 5Rheumatology practice, Goslar, Germany
  6. 6Schlosspark Klinik, Department of Internal Medicine II, Rheumatology, Charité–Universitätsmedizin Berlin Teaching Hospital, Berlin, Germany
  7. 7Rheumatology practice, München, Germany
  8. 8Radiology in Rheumatology practice, Düsseldorf, Germany
  9. 9Faculty of Autoimmundiagnostics, Labor Berlin–Charité Vivantes GmbH, Berlin, Germany
  1. Correspondence to Dr Jacqueline Detert, Department of Rheumatology and Clinical Immunology, Charité–Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany; jacqueline.detert{at}charite.de

Abstract

Objective To investigate the long-term effects of induction therapy with adalimumab (ADA) plus methotrexate (MTX) in comparison with placebo (PBO) plus MTX in DMARD-naïve patients with active early rheumatoid arthritis (RA).

Methods Patients with active early RA (disease duration of ≤12 months) were randomly assigned to receive 40 mg ADA subcutaneously every other week (eow) plus MTX 15 mg/week subcutaneously or PBO plus MTX subcutaneously at 15 mg/week over 24 weeks. Thereafter, all patients received MTX monotherapy up to week 48. The primary outcome was the Disease Activity Score 28 (DAS28) at week 48. Secondary outcomes included proportions of patients in remission (DAS28<2.6), ACR responses, Health Assessment Questionnaire (HAQ) score and radiographic progression.

Results 87 patients were assigned to ADA/MTX and 85 patients to PBO/MTX. At baseline, DAS28 was 6.2±0.8 in the ADA/MTX and 6.3±0.9 in the PBO/MTX groups. At week 24, treatment with ADA/MTX compared with PBO/MTX resulted in a greater reduction in DAS28 (3.0±1.2 vs 3.6±1.4; p=0.009) and other secondary outcomes such as DAS28 remission rate (47.9% vs 29.5%; p=0.021) and HAQ (0.49±0.6 vs 0.72±0.6; p=0.0014). At week 48, the difference in clinical outcomes between groups was not statistically significant (DAS28: 3.2±1.4 vs 3.4±1.6; p=0.41). Radiographic progression at week 48 was significantly greater in patients administered PBO/MTX (Sharp/van der Heijde score: ADA/MTX 2.6 vs PBO/MTX 6.4; p=0.03, Ratingen score: 1.7 vs 4.2; p=0.01).

Conclusions A greater reduction in radiographic progression after initial combination therapy with ADA and MTX was seen at week 48, even after discontinuation of ADA treatment at week 24. This sustained effect was not found at the primary endpoint (DAS28 reduction).

Statistics from Altmetric.com

Footnotes

  • Trial registration http://www.controlled-trials.com: ISRCTN36745608; EudraCT Number: 2006-003146-41.

  • Funding This study was funded by the German Federal Ministry of Education and Research (BMBF, grant number: 01KG0602), trial designation: High Induction Therapy with Anti-Rheumatic Drugs–HIT HARD. Adalimumab was provided by Abbott Co., Wiesbaden, Germany, under an unconditional scientific grant. Abbott had no influence on trial design, interpretation of the data or writing of the paper.

  • Competing interests GRB and KK have received honoraria from Abbott for speaking, board membership and lectures.

  • Ethics approval This study was conducted with the approval of the Berlin State ethics committee (Landesethikkommission Berlin).

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Correction notice This article has been corrected since it was published online first. The Acknowledgements section has been altered.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.